Polyosides (encapsulated bacteria)

Comptes Rendus de l'Academie des Sciences - Serie III

Volumn 322, Issue 11, 1999, Pages 925-932

  Lindberg, Alf A ^a  

^a Pasteur Merieux Connaught   (France)

Author keywords

Antibodies; Bacteria; Encapsulated; Glycoconjugate; Memory; Polysaccharide

Indexed keywords

ANTIBODY; BACTERIAL POLYSACCHARIDE; COMPLEMENT; GLYCOCONJUGATE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; BACTERIAL MEMBRANE; BACTERIAL VIRULENCE; CONFERENCE PAPER; COVALENT BOND; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS INFLUENZAE TYPE B; HOST; HUMAN; IMMUNIZATION; NEISSERIA MENINGITIDIS; OPSONIZATION; PHAGOCYTOSIS; SALMONELLA TYPHI; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

BACTERIA (MICROORGANISMS); HAEMOPHILUS; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS INFLUENZAE SEROTYPE B; NEISSERIA MENINGITIDIS; SALMONELLA TYPHI; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0033230993     PISSN: 07644469     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0764-4469(00)87188-7     Document Type: Conference Paper

References (78)

1. Finland M.D., Dowling H.F., A study of the cutaneous reactions and antibody responses to intramuscular injection of pneumococcus polysaccharides, J. Immunol. 29 (1935) 285-299.
2. Ruegsegger J.M., Finland M., The influence of dosage and route of injection on the antibody response of human subjects to the specific carbohydrate of the type VIII pneumococcus, J. Clin. Invest. 14 (1935) 833-836.
3. Lister S., Ordman D., South African Inst. Med. Res. 7 (1935).
4. MacIeod C.M., Hodge S.R.G., Heidelberger M., Bernhard W.G., Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides, J. Exp. Med. 82 (1945) 445-465.
5. Sutliff W.D., Finland M., Antipneumococcal reactions of human subjects of different ages, J. Exp. Med. 55 (1932) 837-852.
6. Davis J.A.V., J. Immunol. 33 (1939) 1.
7. Fothergill L.D., Wright J.J., Relation of age incidence to the bactericidal power of blood against the causal organism, Immunology 24 (1933) 273-284.
8. Ward H.K., Lyons C., J. Exp. Med. 61 (1935) 515.
9. Pittman M., The action of type-specific Haemophilus influenzae antiserum, J. Exp. Med. 58 (1933) 683-706.
10. Avery O.T., Goebel W.F., Chemo-immunological studies on conjugated carbohydrate-proteins. Part II: Immunological specificity of synthetic sugar-proteins, J. Exp. Med. 50 (1929) 521-533.
11. Goebel W.F., Studies on antibacterial immunity induced by artificial antigen. Part I: Immunity to experimental pneumococcal infection with an antigen containing cellobiuronic acid, J. Exp. Med. 69 (1939).
12. Peltola H., Käyhty H., Sivonen A., Haemophilus influenzae type b capsular polysaccharide vaccine in children: A double-blind field trial of 100,000 vaccines 3 months to 5 years of age in Finland, Paediatrics 60 (1977) 730-737.
13. Takala A.K., Eskola J., VanAlphen L., Spectrum of invasive Haemophilus influenzae type b disease in adults, Arch. Intern. Med. 150 (1990) 2573-2576.
14. Mäkelä P.H., Peltola H., Käyhty H., Jousimies H., Pettay O., Ruoslahti E., Sivonen A., Renkonen O.V., Polysaccharide vaccines of group A Neisseria meningtitidis and Haemophilus influenzae type b: A field trial in Finland, J. Infect. Dis. 136 (Suppl.) (1977) S43-50.
15. Anderson P., Pichichero M.E., Insel R.A., Immunogens consisting of oligosaccharides from the capsule of Haemophilus influenzae type b coupled to diphtheria toxoid or the toxin protein CRM197, J. Clin. Invest. 76 (1985) 52-59.
16. Schneerson R., Barrera O., Sutton A., Robbins J.B., Preparation characterization and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates, J. Exp. Med. 152 (1980) 361-376.
17. Schneerson R., Robbins J.B., Parke Jr J.C., Bell C., Schlesselman J.J., Sutton A., Wang Z., Schiffman G., Karpas A., Shiloach J., Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates, Infect. Immun. 52 (1986) 519-528.
18. Vella P.P., Marburg S., Staub J.M., Kniskern P.J., Miller W., Hagopian A., Ip C., Tolman R.L., Rusk C.M., Chupak L.S., Ellis, R.W., Immunogenicity of conjugate vaccines consisting of pneumococcal capsular polysaccharide types 6B, 14, 19F, and 23F and a meningococcal outer membrane protein complex, Infect. Immun. 60 (1992) 4977-4983.
19. Robbins J.B., Parke Jr J.C., Schneerson R., Whisnant J.K., Quantitative measurement of 'natural' and immunization-induced Haemophilus influenzas type b capsular polysaccharide antibodies, Pediatr. Res. 7 (1973) 103-110.
20. Käyhty H., Peltola H., Karanko V., Mäkela P.H., The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b, J. Infect. Dis. 147 (1983) 1100.
21. Goldblatt D., Vaz A.R., Miller E., Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization, J. Infect. Dis. 177 (1998) 1112-1115.
22. Peltola H., Kilpi T., Anttila M., Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunisation with conjugate vaccines, Lancet 340 (1992) 592-594.
23. Booy R., Heath P.T., Slack M.P., Begg N., Moxon E.R., Vaccine failures after primary immunisation with Haemophilus influenzae type-b conjugate vaccine without booster, Lancet 349 (1997) 1197-1202.
24. Adams W.G., Deaver K.A., Cochi S.L., Plikaytis B.D., Zell E.R., Broome C.V., Wenger J.D., Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era, JAMA 269 (1993) 221-226.
25. Takala A.K., Eskola J., Leinonen M., Kayhty H., Nissinen A., Pekkanen E., Makela P.H., Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine, J. Infect. Dis. 164 (1991) 982-986.
26. Barbour M.L., Mayon-White R.T., Coles C., Crook D.W., Moxon E.R., The impact of conjugate vaccine on carriage of Haemophilus influenzae type b, J. Infect. Dis. 171 (1995) 93-98.
27. Käyhty H., Eskola J., Peltola H., Ronnberg P.R., Kela E., Karanko V., Saarinen L., Antibody responses to four Haemophilus influenzae type b conjugate vaccines, Am. J. Dis. Child. 145 (1991) 223-227.
28. Castillo de Febres O., Decker M.D., Estopinan M., Bordones G., Edwards K.M., Enhanced antibody response in venezuelan infants immunized with Haemophilus influenzae type b-tetanus toxoid conjugate vaccine, Pediatr. Infect. Dis. J. 13 (1994) 635-639.
29. Pandey J., Genetics of immunoglobulins, in: Virella G. (Ed.), Introduction to Medical Immunology, 3rd Ed., Marcel Dekker, New York, 1993, pp. 103-116.
30. Granoff D.M., Boies E., Squires J., Pandey J.P., Suarez B., Oldfather J., Rodey G.E., Interactive effect of genes associated with immunoglobulin allotypes and HLA specificities on susceptibility to Haemophilus influenzae disease, J. Immunogenet. 11 (1984) 181-188.
31. Granoff D.M., Shackelford P.G., Suarez B.K., Nahm M.H., Cates K.L., Murphy T.V., Karasic R., Osterholm M.T., Pandey J.P., Daum R.S., Haemophilus influenzae type b disease in children vaccinated with type b polysaccharide vaccine, New Engl. J. Med. 315 (1986) 1584-1590.
32. Black F.L., Schiffman G., Pandey J.P., HLA, Gm, and Km polymorphisms and immunity to infectious diseases in south amerinds, Exp. Clin. Immunogenet. 12 (1995) 206-216.
33. Goldblatt D., Scadding G.K., Lund V.J., Wade A.M., Turner M.W., Pandey J.P., Association of Gm allotypes with the antibody response to the outer membrane proteins of a common upper respiratory tract organism, Moraxella catarrhalis, J. Immunol. 153 (1994) 5316-5320.
34. Ambrosino D.M., Barrus V.A., Delange G.G., Siber G.R., Correlation of the Km (1) immunoglobulin allotype with anti-polysaccharide antibodies in Caucasian adults, J. Clin. Invest. 78 (1986) 361-365.
35. Pandey J.P., Fudenberg H.H., Virella G., Kyong C.U., Loadholt C.B., Galbraith R.M., Gotschlich E.C., Parke Jr J.C., Association between immunoglobulin allotypes and immune responses to Haemophilus influenzae and Meningococcus polysaccharides, Lancet 1 (1979) 190-192.
36. Weinberg G.A., Granoff D.M., Immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugate vaccines in children with conditions associated with impaired antibody responses to type b polysaccharide vaccine, Pediatrics 85 (1990) 654-661.
37. Follin P., Ulanova M., Hahn-Zoric M., Hanson L.A., Invasive Haemophilus influenzae type b (Hib) infection in an adult patient with a selective deficiency of antibody to the Hib capsular polysaccharide, Clin. Infect. Dis. 25 (1997) 915-917.
38. Granoff D.M., Suarez B.K., Pandey J.P., Shackelford P.G., Genes associated with the G2m (23) immunoglobulin allotype regulate the igg subclass responses to Haemophilus influenzas type b polysaccharide vaccine, J. Infect. Dis. 157 (1988) 1142-1149.
39. Henrichsen J., Six newly recognized types of Streptococcus pneumoniae, J. Clin. Microbiol. 33 (1995) 2759-2762.
40. Van Dam J.E., Fleer A., Snippe H., Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides, Antonie Van Leeuwenhoek 58 (1990) 1-47.
41. Fedson D.S., Musher D.M., In: Plotkin S.A., Mortimer Jr E.A. (Eds.), Vaccines,Saunders, Philadelphia, 1994, pp. 517-565
42. Gray B.M., Turner M.E., Dillon Jr H.C., Epidemiologic studies of Streptococcus pneumoniae in infants. The effects of season and age on pneumococcal acquisition and carriage in the first 24 months of life, Am. J. Epidemiol. 116 (1982) 692-703.
43. Rosen C., Christensen P., Hovelius B., Prellner K., A longitudinal study of the nasopharyngeal carriage of pneumococci as related to pneumococcal vaccination in children attending day-care centres, Acta Otolaryngol. (Stockh) 98 (1984) 524-532.
44. Todd J.K., Bacteriology and clinical relevance of nasopharyngeal and oropharyngeal cultures, Pediatr. Infect. Dis. 3 (1984) 159-163.
45. Jernigan D.B., Cetron M.S., Breiman R.F., Minimizing the impact of drug-resistant Streptococcus pneumoniae (DRSP). A strategy from the DRSP working group, JAMA 275 (1996) 206-209.
46. Word Health Report, Fighting Disease. Fostering Development, World Health Organization, Geneva, 1996.
47. Robbins J.B., Austrian R., Lee C.J., Rastogi S.C., Schiffman G., Henrichsen J., Makela P.H., Broome C.V., Facklam R.R., Tiesjema R.H., Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups, J. Infect. Dis. 148 (1983) 1136-1159.
48. Leinonen M., Sakkinen A., Kalliokoski R., Luotonen J., Timonen M., Makela P.H., Antibody response to 14-valent pneumococcal capsular polysaccharide vaccine in pre-school age children, Pediatr. Infect. Dis. 5 (1986) 39-44.
49. Eskola J., Käyhty H., Pneumococcal vaccines, Clin. Paediatrics 5 (1997) 101-120.
50. Sniadack D.H., Schwartz B., Lipman H., Bogaerts J., Butler J.C., Dagan R., Echaniz-Aviles G., Lloyd-Evans N., Fenoll A., Girgis N.I., Potential interventions for the prevention of childhood pneumonia: Geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children-implications for vaccine strategies, Pediatr. Infect. Dis. J. 14 (1995) 503-510.
51. Eby R., Koster M., Hogerman D., Pneumococcal conjugates, in: Norrby E., Brown F., Chanock R.M., Ginsberg H.S. (Eds.), Vaccines '94; Modern Approaches to New Vaccines Including Prevention of AIDS, Cold Spring Harbor Laboratory Press, New York, 1994, pp. 119-124.
52. DiJohn D., Wasserman S.S., Torres J.R., Cortesia M.J., Murillo J., Losonsky G.A., Herrington D.A., Sturcher D., Levine M.M., Effect of priming with carrier on response to conjugate vaccine, Lancet 2 (1989) 1415-1418.
53. Peeters C.C., Tenbergen-Meekes A.M., Poolman J.T., Beurret M., Zegers B.J., Rijkers G.T., Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines, Infect. Immun. 59 (1991) 3504-3510.
54. Powers D.C., Anderson E.L., Lottenbach K., Mink C.M., Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults, J. Infect. Dis. 173 (1996) 1014-1018.
55. O'Brien K.L., Steinhoff M.C., Edwards K., Keyserling H., Thoms M.L., Madore D., Immunologic priming of young children by pneumococcal glycoprotein conjugate, but not polysaccharide, vaccines, Pediatr. Infect. Dis. J. 15 (1996) 425-430.
56. Ahman H., Kayhty H., Lehtonen H., Leroy O., Froeschle J., Eskola J., Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory, Pediatr. Infect. Dis. J. 17 (1998) 211-216.
57. Dagan R., Muallem M., Melamed R., Leroy O., Yagupsky P., Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid, Pediatr. Infect. Dis. J. 16 (1997) 1060-1064.
58. Musher D.M., Groover J.E., Watson D.A., Pandey J.P., Rodriguez- Barradas M.C., Baughn R.E., Pollack M.S., Graviss E.A., de Andrade M., Amos C.I., Genetic regulation of the capacity to make immunoglobulin G to pneumococcal capsular polysaccharides, J. Investig. Med. 45 (1997) 57-68.
59. Riedo F.X., Plikaytis B.D., Broome C.V., Epidemiology and prevention of meningococcal disease, Pediatr. Infect. Dis. J. 14 (1995) 643-657.
60. Jackson L.A., Schuchat A., Reeves M.W., Wenger J.D., Serogroup C meningococcal outbreaks in the United States. An emerging threat [see comments], JAMA 273 (1995) 383-389.
61. Peltola H., Meningococcal vaccines. Current status and future possibilities, Drugs 55 (1998) 347-366.
62. Peltola H., Kataja J.M., Mäkela P.H., Shift in the age-distribution of meningococcal disease as predictor of an epidemic?, Lancet 2 (1982) 595-597.
63. Flexner S., The results of serum treatment in 1 300 cases of epidemic meningitis, J. Exp. Med. 17 (1913) 553-576.
64. Fairley C.K., Begg N., Borrow R., Fox A.J., Jones D.M., Cartwright K., Conjugate meningococcal serogroup A and C vaccine: Reactogenicity and immunogenicity in United Kingdom infants, J. Infect. Dis. 174 (1996) 1360-1363.
65. Twumasi Jr P.A., Kumah S., Leach A., O'Dempsey T.J., Ceesay S.J., Todd J., Broome C.V., Carlone G.M., Pais L.B., Holder P.K., Plikaytis B.D., Greenwood B.M., A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants, J. Infect. Dis. 171 (1995) 632-638.
66. Lieberman J.M., Chiu S.S., Wong V.K., Partidge S., Chang S.J., Chiu C.Y., Gheesling L.L., Carlone G.M., Ward J.I., Safety and immunogenicity of a serogroups A/C neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. A randomized controlled trial, JAMA 275 (1996) 1499-1503.
67. Leach A., Twumasi P.A., Kumah S., Banya W.S., Jaffar S., Forrest B.D., Granoff D.M., Libutti D.E., Carlone G.M., Pais L.B., Broome C.V., Greenwood B.M., Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine, J. Infect. Dis. 175 (1997) 200-204.
68. Wyle F.A., Artenstein M.S., Brandt B.L., Tramont E.C., Kasper D.L., Altieri P.L., Berman S.L., Lowenthal J.P., Immunologic response of man to group B meningococcal polysaccharide vaccines, J. Infect. Dis. 126 (1972) 514-521.
69. Finne J., Leinonen M., Mäkela P.H., Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis, Lancet 2 (1983) 355-357.
70. Lifely M.R., Moreno C., Vaccine against meningococcal group B disease, Lancet 1 (1986) 214-215.
71. Mandrell R.E., Azmi F.H., Granoff D.M., Complement-mediated bactericidal activity of human antibodies to poly-a2, 8 N-acetylneuraminic acid, the capsular polysaccharide of Neisseria meningitidis serogroup B, J. Infect. Dis. 172 (1995) 1279-1289.
72. Jennings H.J., Roy R., Gamian A., Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine, J. Immunol. 137 (1986) 1708-1713.
73. Pon R.A., Lussier M., Yang Q.L., Jennings H.J., N-propionylated group B meningococcal polysaccharide mimics a unique bactericidal capsular epitope in group B Neisseria meningitidis, J. Exp. Med. 185 (1997) 1929-1938.
74. Wessels M.R., Paoletti L.C., Rodewald A.K., Michon F., Difabio J., Jennings H.J., Kasper D.L., Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type ia polysaccharide-tetanus toxoid conjugate vaccine, Infect. Immun. 61 (1993) 4760-4766.
75. Marques M.B., Kasper D.L., Shroff A., Michon F., Jennings H.J., Wessels M.R., Functional activity of antibodies to the group B polysaccharide of group B streptococci elicited by a polysaccharide-protein conjugate vaccine, Infect. Immun. 62 (1994) 1593-1599.
76. Szu S.C., Taylor D.N., Trofa A.C., Clements J.D., Shiloach J., Sadoff J.C., Bryla D.A., Robbins J.B., Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines, Infect. Immun. 62 (1994) 4440-4444.
77. Cross A.S., Sadoff J.C., Furer E., Cryz Jr S.J., Escherichia coli and Klebsiella vaccines and immunotherapy, Infect. Dis. Clin. North Am. 4 (1990) 271-282.
78. Cryz Jr S.J., Que J.O., Cross A.S., Furer E., Synthesis and characterization of a polyvalent Escherichia coli O- polysaccharide-toxin A conjugate vaccine, Vaccine 13 (1995) 449-445.